

## Short Communication

# Threshold to *N*-methyl-D-aspartate-induced seizures in mice undergoing chronic nutritional magnesium deprivation is lowered in a way partly responsive to acute magnesium and antioxidant administrations

Pierre Maurois<sup>1,2,†</sup>, Nicole Pages<sup>3,†</sup>, Pierre Bac<sup>1,2</sup>, Michèle German-Fattal<sup>1,2</sup>, Geneviève Agnani<sup>4</sup>, Bernadette Delplanque<sup>4</sup>, Jean Durlach<sup>5</sup>, Jacques Poupaert<sup>6</sup> and Joseph Vamecq<sup>7\*</sup>

<sup>1</sup>Faculté de Pharmacie, Université Paris Sud 11, F-92296 Châtenay-Malabry, France

<sup>2</sup>CNRS UMR 8162, IFR 13, Centre Chirurgical Marie Lannelongue, F-92350 Le Plessis Robinson, France

<sup>3</sup>Laboratoire de Toxicologie, Faculté de Pharmacie, Université Louis Pasteur, F-67401 Illkirch, France

<sup>4</sup>NMPA, University of Paris XI, Orsay, France

<sup>5</sup>SDRM, Université Pierre et Marie Curie, Paris VI, Paris, France

<sup>6</sup>Department of Medicinal Chemistry, School of Pharmacy, UCL, Brussels, Belgium

<sup>7</sup>INSERM Univ 045131, EA1046 Lille, France

(Received 13 February 2008 – Revised 6 May 2008 – Accepted 6 May 2008 – First published online 16 June 2008)

Magnesium deficiency may be induced by a diet impoverished in magnesium. This nutritional deficit promotes chronic inflammatory and oxidative stresses, hyperexcitability and, in mice, susceptibility to audiogenic seizures. Potentiation by low-magnesium concentrations of the opening of *N*-methyl-D-aspartate (NMDA) receptor/calcium channel in *in vitro* and *ex vivo* studies, and responsiveness to magnesium of *in vivo* brain injury states are now well established. By contrast, little or no specific attention has been, however, paid to the *in vivo* NMDA receptor function/excitability in magnesium deficiency. The present work reports for the first time that, in mice undergoing chronic nutritional deprivation in magnesium (35 v. 930 parts per million for 27 d in OF1 mice), NMDA-induced seizure threshold is significantly decreased (38 % of normal values). The attenuation in the drop of NMDA seizure threshold (percentage of reversal) was 58 and 20 % upon acute intraperitoneal administrations of magnesium chloride hexahydrate (28 mg magnesium/kg) and the antioxidant ebselen (20 mg/kg), respectively. In nutritionally magnesium-deprived animals, audiogenic seizures are completely prevented by these compound doses. Taken as a whole, our data emphasise that chronic magnesium deprivation in mice is a nutritional *in vivo* model for a lowered NMDA receptor activation threshold. This nutritional model responds remarkably to acute magnesium supply and moderately to acute antioxidant administration.

**Nutritional magnesium deprivation: *N*-methyl-D-aspartate receptor: Ebselen: Magnesium chloride hexahydrate: *N*-methyl-D-aspartate-induced seizure: Seizure threshold: Audiogenic seizures**

Magnesium and its deficiency present with many facets. The magnesium blockade of the *N*-methyl-D-aspartate (NMDA) receptor–calcium channel was reported more than 20 years ago<sup>(1)</sup>. Magnesium deficiency, which may be induced by chronic nutritional deprivation, has been shown to be a particular state affecting a great many tissue and cell physiological events. Among others, magnesium deficiency induces inflammatory and oxidative stresses, being associated with central hyperexcitability<sup>(2)</sup> and susceptibility towards audiogenic seizures. These seizures, which develop into four successive phases (latency, wild running, seizure and recovery), have been shown to respond to both anticonvulsant and neuroprotective compounds in a relatively discriminative

way<sup>(3–5)</sup>. Protection given by compounds in this peculiar nutritional model may result from either intrinsic anti-seizure or intrinsic antioxidant/anti-inflammatory neuroprotective properties, or both.

Magnesium occupancy of the calcium channel lumen of the NMDA receptor results in a physiological block, which needs to be removed to allow the entry of calcium into the cell via this channel. In this respect, Nowak *et al.*<sup>(1)</sup> in their initial work demonstrated that NMDA receptor–calcium channel opening was greatly potentiated by exposure to low-magnesium concentrations. Despite this finding being corroborated by many *in vitro* and *ex vivo* (tissue slices) experiments, little or no direct information is currently available about this relationship in the

**Abbreviation:** NMDA, *N*-methyl-D-aspartate.

\* **Corresponding author:** Joseph Vamecq, fax +33 320 44 53 93, email joseph.vamecq@inserm.fr

† These authors contributed equally to the present work.

whole animal; notably, the susceptibility of magnesium-deprived mice to seizures induced by a compound selectively targeting the NMDA receptor function, for instance NMDA, remains to be explored. So, this work was aimed at determining in chronic nutritional magnesium deprivation (*v.* normal nutritional magnesium intake conditions) the status of the threshold for NMDA-induced seizures. Responses to magnesium chloride hexahydrate and ebselen (a glutathione peroxidase mimic antioxidant chosen here to depress oxidative stress taking place in magnesium deficiency) were determined. Susceptibility to audiogenic seizures was also studied.

## Materials and methods

### Compounds

Magnesium chloride hexahydrate, magnesium sulphate heptahydrate, ebselen, NMDA, dimethylsulfoxide (DMSO) and polyethylene glycol 300 (PEG 300) were from Sigma-Aldrich Fine Chemicals (St Quentin Fallavier, France).

### Experimental protocols

The present experimental protocols and procedures complied with the European Communities Council Directives of 24 November 1996 (86/609/EEC).

### Chronic nutritional magnesium deprivation protocol

Nutritional magnesium deprivation was performed as described in the work of Bac *et al.*<sup>(3)</sup>, except that a 35 ppm instead of a 50 parts per million (ppm) magnesium content of the diet was used here in order to induce in adult OF1 mice (Janvier, Le Genest St Isle, France) susceptibility to audiogenic seizures in 100% animals over a period of 27 d instead of 42 d. The control and magnesium-deficient semi-synthetic diets were essentially prepared as described by Rayssiguier's group<sup>(6,7)</sup>, and in this study they contained (g/kg): 200 casein; 700 sucrose; 10 sunflower oil; 40 corn oil; 3 D,L-methionine; 2 phosphorylcholine; 35 modified AIN-76 mineral mix; 10 AIN-76A vitamin mix (ICN Biomedicals, Orsay, France). MgO was omitted from the mineral mix in the magnesium-deficient diet. The diets were stored at  $-20^{\circ}\text{C}$  before being lyophilised and compacted until consumption by the mice as described elsewhere<sup>(7)</sup>. Magnesium contents of the diets were determined as described in a previous work<sup>(3)</sup>. The diets were high in the oxidant stressor fructose<sup>(8)</sup> and low in anti-inflammatory *n*-3 fatty acids. OF1 mice were chosen because their use as animals undergoing magnesium deficiency has been largely described in the literature. A major reason could be that, in contrast to some other mouse strains, deaths in OF1 mice submitted to severe nutritional magnesium deprivation remain occasional only. For instance, this strain may survive successfully to long periods (6 months) of severe nutritional magnesium deprivation<sup>(9)</sup>.

### Susceptibility to audiogenic seizures

Essentially, the audiogenic seizure test was started by exposing tested animals to a 15 s auditory signal of  $10 \pm 0.1$  kHz frequency and  $100 \pm 1$  db intensity. The intensity of 100 db

characterising the 10 kHz acoustic stimulus is the intensity previously used to validate and standardise the audiogenic test; it usually induces audiogenic seizures in 90–100% of OF1 mice fed on the present magnesium-deprived diet. The 10 kHz frequency is the frequency at which magnesium-deficient, and not control, OF1 mice develop audiosensitive seizures.

Development of these seizures was characterised by the succession of four phases (latency, wild running, seizure and recovery) as previously described<sup>(3–5)</sup>.

### Susceptibility to N-methyl-D-aspartate-induced seizures

NMDA was dissolved in a 0.9% saline solution and was administered by the intraperitoneal route, and the lowest dose of NMDA inducing lethal seizures in 100% animals was determined. This dosage was referred to as the threshold for NMDA-induced seizures.

### Reversion of susceptibility to seizures by acute compound administration

Acute administration of compounds (magnesium chloride hexahydrate (see the range of given doses in the next paragraph) and 20 mg/kg ebselen) was performed intraperitoneally 30 min before the administration of NMDA or exposure to the acoustic stimulus. Solubilisation of compounds prior to the administration was performed as follows: magnesium chloride hexahydrate was dissolved in a 0.9% saline water solution, and ebselen in a 10  $\mu\text{l}$  DMSO/10  $\mu\text{l}$  PEG 300 mixture solution. At these dosages, the vehicles (saline, DMSO/PEG 300) were without significant effects on the parameters investigated throughout this study.

### Acute administration of magnesium

The amount of magnesium ingested by mice given the deficient diet corresponded to *grosso modo* a daily supply of 5.6 mg magnesium/kg body weight. A half to several folds of this daily dose was given to mice acutely by the intraperitoneal route in the form of magnesium chloride hexahydrate, 46.8 mg of which contained 5.6 mg magnesium.

### Statistical analysis

Quantitative data were expressed as the means with their standard errors for each treatment group. Means were compared using ANOVA with Fischer's, Scheffe's or Dunnett's multiple comparison of means test (StatView<sup>TM</sup> 512+, Brain Power, Inc., Calabasas, CA).

## Results

### Susceptibility of magnesium-deprived animals to N-methyl-D-aspartate-induced seizures

In magnesium-deprived mice, threshold to NMDA-induced seizures was lowered to 38% of normal values, normal and deficient animals having thresholds equal to 137 and 52 mg NMDA/kg, respectively (Table 1).

**Table 1.** Comparative seizure susceptibility of mice given a standard animal chow and a magnesium-deprived diet, and ability of compounds to reverse changes related to magnesium deprivation

	Control mice	Magnesium-deprived mice		
	No compounds	No compounds	Magnesium (28 mg/kg)	Ebselen (20 mg/kg)
Sensitivity to audiogenic seizures (%)	0	100	0	0
Sensitivity to NMDA-induced seizures (threshold expressed as mg NMDA/kg)	137 (SEM 1)	52 (SEM 1) <sup>a</sup>	101 (SEM 4) <sup>b,c</sup>	69 (SEM 2) <sup>a,d</sup>

The results are mean values expressed as percentages of unprotected animals for mice submitted to the audiogenic seizure test, and are means with their standard errors for mice given *N*-methyl-D-aspartate (NMDA) (*n* 6).

<sup>a</sup>*P*<0.001 (comparison of magnesium-deprived mice with controls).

<sup>b</sup>*P*<0.01 (comparison of magnesium-deprived mice with controls).

<sup>c</sup>*P*<0.001 (comparison of magnesium-deprived mice given a compound with deficient mice that received no compounds).

<sup>d</sup>*P*<0.01 (comparison of magnesium-deprived mice given a compound with deficient mice that received no compounds).

### Susceptibility of magnesium-deficient mice to audiogenic seizures

The nutritional protocol was characterised by the magnesium content of the diet and duration of diet administration such that the resulting magnesium deprivation caused a susceptibility to audiogenic seizures in 100% of tested magnesium-deprived animals (Table 1). By contrast, mice given the control diet and exposed to the acoustic stimulus were all refractory to audiogenic seizure development (Table 1).

### Reversion of susceptibilities to seizures

The drop induced by magnesium deficiency in the threshold to NMDA-induced seizures was partly reversed by acute administrations of 28 mg/kg magnesium (58% of reversal) and 20 mg/kg antioxidant ebselen (20% of reversal; Table 1). Increasing the doses of each element or compound did not lead to substantial gain in reversing the threshold shift, magnesium doses superior to 30 mg/kg body weight (from 30 to 40 mg/kg) became progressively toxic and finally lethal for the magnesium-deficient animals (data not shown).

Susceptibility of magnesium-deprived mice to audiogenic seizures was fully reversed by either 28 mg/kg magnesium or 20 mg/kg ebselen (Table 1).

A similar dose of magnesium given in the form of magnesium sulphate heptahydrate instead of magnesium chloride hexahydrate was also successful in enhancing by a comparable percentage the threshold to NMDA-induced seizures and to protect completely magnesium-deficient animals against audiogenic seizures (data not shown).


### Other aspects of susceptibilities and reversals

The extent of magnesium to restore, in magnesium-deprived mice, threshold to NMDA-induced seizures and protection against audiogenic seizure was found to be dose dependent (Fig. 1). When 2.8, 5.6 or 11.2 mg/kg magnesium was given in a single dose, no substantial increase of threshold to NMDA-induced seizures was observed in magnesium-deficient mice. Acute administrations of 16.8 and 22.4 mg/kg magnesium enhanced partially and progressively the threshold to NMDA-induced seizures in deficient animals. The latter two magnesium doses provided mice with full protection against audiogenic seizures. The 11.2 mg/kg magnesium corresponded to a dose protecting 50% of animals against

audiogenic seizures. The acute administration of 5.6 mg/kg magnesium was sufficient to protect a weak percentage of animals against audiogenic seizures, while halving this acute administration of magnesium was devoid of protective effects towards the development of these seizures.

### Discussion

This work shows that, in the whole animal, chronic nutritional magnesium deprivation lowers seizure threshold to NMDA. Partial but substantial reversion of this effect by acute magnesium chloride (notably 28 mg magnesium/kg) might result from increasing magnesium availability and hence magnesium block within the calcium channel of NMDA receptor. Reversion by ebselen was lower. It might be linked to redox sensitivity of NMDA receptor, ebselen having been previously



**Fig. 1.** Differential effect of acute magnesium administrations on audiogenic seizure susceptibility (■) and *N*-methyl-D-aspartate (NMDA) seizure threshold lowering (□) encountered in the mice fed a diet impoverished in magnesium. Each group of mice (*n* 6) was given chronically the magnesium-deficient diet before being (2.8, 5.6, 11.2, 16.8, 22.5 and 28 mg magnesium/kg body weight) or not (No) submitted to acute magnesium administration. Note that the effects illustrated in this figure and those shown in Table 1 are induced by the tested compounds (here, magnesium chloride hexahydrate) 30 min after the intraperitoneal administration. \* and \*\*: *P*<0.005 and *P*<0.001, respectively (comparison of mice given acute magnesium v. the 'no' group). † and ‡: *P*<0.01 and *P*<0.001, respectively (comparison is made between 22.4 and 28 mg/kg groups with the group of mice given 16.8 mg/kg magnesium). §: *P*<0.01 when comparing the groups of mice receiving 28 mg/kg with the group given 22.4 mg/kg magnesium.

shown to interact with the redox modulatory site of NMDA receptor<sup>(10)</sup>. The weak impact of ebselen on NMDA receptor excitability shown here in magnesium-deprived animals might be in agreement with its limited neuroprotective activity in preclinical and clinical studies<sup>(11)</sup>. By contrast, the rapidity and extent to which acute administration of magnesium chloride hexahydrate restored NMDA-induced seizure threshold suggest major, though not strict, magnesium dependency of threshold reduction occurring during chronic nutritional magnesium deprivation. Magnesium chloride effects reported here were on the other hand mimicked by magnesium sulphate. This potent action of magnesium salts on the NMDA receptor might explain the success of magnesium-based therapies in neurological stress or insult<sup>(12–14)</sup>. In contrast to NMDA-induced seizures, audiogenic seizures were fully responsive to acute administrations of magnesium chloride hexahydrate and ebselen. In understanding the mechanisms by which an antioxidant compound such as ebselen (this work) or a synthetic ovothiol analogue<sup>(5)</sup> prevents audiogenic seizures, we should take into account that, importantly, these and other antioxidants/anti-inflammatory compounds do not control acutely the seizures in classic animal models and hence in human epileptic patients. Their activity in audiogenic seizures might hold in the audiogenic nature of seizures, which develops in conditions, for instance exposure to kanamycin<sup>(15)</sup>, cerebral ischaemia<sup>(16,17)</sup> or magnesium deprivation<sup>(3)</sup>, associated with free radical generation<sup>(18–23)</sup>, ebselen being capable of preventing noise-induced toxicity<sup>(24)</sup>.

Enrichment of the magnesium-deficient diet with *n*-3 fatty acids (i.e. full replacement of sunflower and corn oils by rapeseed (colza) oil in the semi-synthetic diet) had little to no effect in the decrease of NMDA-induced seizure threshold (the authors, unpublished results), while it reduced the number of mice becoming sensitive to audiogenic seizures<sup>(25)</sup>, further validating the view that audiogenic seizures are more sensitive than NMDA-induced seizures to antioxidant manipulations during magnesium deficiency.

In this respect, the better sensitivity to magnesium of audiogenic seizures (v. NMDA-induced seizures) might be accounted for by anti-inflammatory<sup>(26)</sup> and/or antioxidant properties of magnesium. Magnesium is a cofactor for the enzymes in glutathione biosynthesis ( $\gamma$ -glutamylcysteine synthetase and glutathione synthetase)<sup>(27,28)</sup> and NADPH-producing pentose phosphate pathway (6-phosphogluconate dehydrogenase and transketolase)<sup>(29,30)</sup>, explaining why magnesium may affect glutathione biosynthesis and recycling. In normal diet conditions, the physiological cellular loss of reduced glutathione is balanced by substantial intracellular biosynthesis rates. In magnesium deficiency, cellular loss is maintained, whereas biosynthesis decreases, resulting in a net depletion in cellular levels in reduced glutathione (and hence in antioxidant defences)<sup>(20)</sup>. Reversing magnesium levels (as performed here by acute magnesium administrations) can restore biosynthesis enzyme activities and hence cell antioxidant status<sup>(20)</sup>. The latter antioxidant properties of magnesium are consistent with its protective properties towards audiogenic seizures.

#### Acknowledgements

No conflict of interest was associated with the present study. Contribution of each author to this Short Communication

was as follows: P. M. and N. P. performed most experiments; P. B. and M. G.-F. provided all the equipment and experience needed for performing these experiments; G. A. and B. D. contributed to the design and elaboration of the control and magnesium-deprived diet; J. D., J. P. and J. V. contributed to the supervision and drafting of the manuscript and to the design of some of the experiments. The authors are indebted to Dr Christopher R. McCurdy (University of Mississippi, Oxford, MS) for revision of the English language.

#### References

- Nowak L, Bregestovski P, Ascher P, Herbert A & Prochiantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. *Nature* **307**, 462–465.
- Durlach J, Bac P, Bara M & Guiet-Bara A (2000) Physiopathology of symptomatic and latent forms of central nervous hyperexcitability due to magnesium deficiency: a current general scheme. *Magnes Res* **13**, 293–302.
- Bac P, Maurois P, Dupont C, Pages N, Stables JP, Gressens P, Evrard P & Vamecq J (1998) Magnesium deficiency-dependent audiogenic seizures (MDDAs) in adult mice: a nutritional model for discriminatory screening of anticonvulsant drugs and original assessment of neuroprotection properties. *J Neurosci* **18**, 4363–4373.
- Maurois P, Rocchi S, Pages N, Bac P, Stables JP, Gressens P & Vamecq J (2008) The PPAR $\gamma$  agonist FMOC-L-leucine protects both mature and immature brain. *Biomed Pharmacother* **62**, 259–263.
- Vamecq J, Maurois P, Bac P, Bailly F, Bernier JL, Stables JP, Husson I & Gressens P (2003) Potent mammalian cerebroprotection and neuronal cell death inhibition are afforded by a synthetic antioxidant analogue of marine invertebrate cell protectant ovothiols. *Eur J Neurosci* **18**, 1110–1120.
- Bussi re FI, Tridon A, Zimowska W, Mazur A & Rayssiguier Y (2003) Increase in complement component C3 is an early response to experimental magnesium deficiency in rats. *Life Sci* **73**, 499–507.
- Maurois P, Gueux E & Rayssiguier Y (1989) Protective effect of severe magnesium deficiency on *Plasmodium chabaudi* infection. *Magnes Res* **2**, 183–187.
- Maurois P, Delcourt PH, Gueux E & Rayssiguier Y (1994) Magnesium deficiency protects against *Babesia hyalomysci* and mice become resistant to rechallenge with the parasite regardless of diet fed. *Parasitology* **108**, 245–248.
- Busserolles J, Gueux E, Rock E, Mazur A & Rayssiguier Y (2003) High fructose feeding of magnesium deficient rats is associated with increased plasma triglyceride concentration and increased oxidative stress. *Magnes Res* **16**, 7–12.
- Herin GA, Du S & Aizenman E (2001) The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. *J Neurochem* **78**, 1307–1314.
- Green AR & Ashwood T (2005) Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. *Curr Drug Targets CNS Neurol Disord* **4**, 109–118.
- Bhudia S, Cosgrove D, Naugle R, *et al.* (2006) Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. *J Thorac Cardiovasc Surg* **131**, 853–861.
- Chan MT, Boet R, Ng SC, Poon WS & Gin T (2005) Magnesium sulfate for brain protection during temporary cerebral artery occlusion. *Acta Neurochir* **95**, Suppl., 107–111.
- Wong GK, Chan MT, Poon WS, Boet R & Gin T (2006) Magnesium therapy within 48 hours of an aneurysmal subarachnoid hemorrhage: neuro-panacea. *Neurol Res* **28**, 431–435.



15. Pierson MG & Swann JW (1988) The sensitive period and optimum dosage for induction of audiogenic seizure susceptibility by kanamycin in the Wistar rat. *Hear Res* **32**, 1–10.
16. Kawai K, Penix LP, Kawahara N, Ruetzler CA & Klatzo I (1995) Development of susceptibility to audiogenic seizures following cardiac arrest cerebral ischemia in rats. *J Cereb Blood Flow Metab* **15**, 248–258.
17. Schurr A, Payne RS, Reid KH, Iyer V, Tseng MT, Li MM, Chan SA, Young C, Miller JJ & Rigor BM (1995) Cardiac arrest-induced global ischemia studied *in vitro*. *Life Sci* **57**, 2425–2430.
18. Kumaran C & Shivakumar K (2001) Superoxide-mediated activation of cardiac fibroblasts by serum factors in hypomagnesemia. *Free Radic Biol Med* **31**, 882–886.
19. Moro MA, Almeida A, Bolaños JP & Lizasoain I (2005) Mitochondrial respiratory chain and free radical generation in stroke. *Free Radic Biol Med* **39**, 1291–1304.
20. Regan RF & Guo Y (2001) Magnesium deprivation decreases cellular reduced glutathione and causes oxidative neuronal death in murine cortical cultures. *Brain Res* **890**, 177–183.
21. Sugawara T & Chan PH (2003) Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. *Antioxid Redox Signal* **5**, 597–607.
22. Takayama M, Yamane H, Konishi K, Iguchi H, Shibata S, Sunami K, Nakai Y & Nakagawa T (1997) Induction of free radicals in the cochlea by an aminoglycoside antibiotic. *Acta Otolaryngol* **528**, Suppl., 19–24.
23. Zhou Q, Olinescu RM & Kummeraw FA (1999) Influence of low magnesium concentrations in the medium on the antioxidant system in cultured human arterial endothelial cells. *Magnes Res* **12**, 19–29.
24. Yamasoba T, Pourbakht A, Sakamoto T & Suzuki M (2005) Ebselen prevents noise-induced excitotoxicity and temporary threshold shift. *Neurosci Lett* **380**, 234–238.
25. Pages N, Maurois P, Agnani G, Vamecq J, Fénart E, Bac P & Delplanque B (2007) Is chronic rapeseed oil diet more neuroprotective than chronic corn/sunflower diet? Evaluation by audiogenic seizure test in magnesium-deficient mice (MDDAS). *OCL (Oléagineux, Corps gras & Lipides)* **14**, 214–215.
26. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W & Rayssiguier Y (2007) Magnesium and the inflammatory response: potential physiopathological implications. *Arch Biochem Biophys* **458**, 48–56.
27. Hsu JM, Rubenstein B & Paleker AG (1982) Role of magnesium in glutathione metabolism of rat erythrocytes. *J Nutr* **112**, 488–496.
28. Mills BJ, Lindeman RD & Lang CA (1986) Magnesium deficiency inhibits biosynthesis of blood glutathione and tumor growth in the rat. *Proc Soc Exp Biol Med* **181**, 326–332.
29. Heinrich PC, Steffen H, Jauser P & Wiss O (1972) Studies on the reconstitution of apotransketolase with thiamin pyrophosphate and analogs of the coenzyme. *Eur J Biochem* **30**, 533–541.
30. Veronese FM, Boccu E, Fontana A, Benassi CA & Scoffone E (1974) Isolation and some properties of 6-phosphogluconate dehydrogenase from *Bacillus stearothermophilus*. *Biochim Biophys Acta* **334**, 31–44.